{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:03:39Z","timestamp":1790291019810,"version":"4.1.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100012659","name":"Canadian Centre for Applied Research in Cancer Control","doi-asserted-by":"publisher","award":["20EA1024"],"award-info":[{"award-number":["20EA1024"]}],"id":[{"id":"10.13039\/100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["26-A-30"],"award-info":[{"award-number":["26-A-30"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cervical cancer remains a concern worldwide, and cervical cancer screening plays an important role in reducing the burden of this disease. Although cytology is still the main strategy for cervical cancer screening, it has gradually changed to human papillomavirus testing. The specificity of human papillomavirus testing is lower than that of cytology, which leads to an increased rate of colposcopy after positive results. To decrease colposcopic examinations, an efficient triage method is needed for human papillomavirus screening. New biomarkers have been developed and evaluated for primary screening and triage of abnormal cytology or human papillomavirus-positive results. Their sensitivity and specificity were estimated and compared with those of cytology. In the present study, the following new techniques were examined: p16\/Ki67 dual staining, DNA methylation, micro-ribonucleic acid, chromosomal abnormalities, Claudins and DNA ploidy. Evaluation studies of p16\/Ki67 dual staining and DNA methylation were more advanced than those of other options. When p16\/Ki67 dual staining was used for triage for human papillomavirus testing, the sensitivity of 2 or greater cervical intraepithelial neoplasia (CIN2+) detection was higher than that of cytology without decreased specificity. Although there are several types of DNA methylation, sensitivity and specificity were moderate for detecting CIN2+. S5 classifier is a commercialized product that consists of viral methylation, and high sensitivity with decreased specificity has been reported. Considering its combination with self-sampling, DNA methylation is a highly anticipated technique along with human papillomavirus testing for the next generation of cervical cancer screening. However, the backgrounds for cervical cancer screening differ among countries and further study is needed to identify the best available method.<\/jats:p>","DOI":"10.1093\/jjco\/hyab109","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T11:09:50Z","timestamp":1624532990000},"page":"1462-1470","source":"Crossref","is-referenced-by-count":8,"title":["Emerging technologies for cervical cancer screening"],"prefix":"10.1093","volume":"51","author":[{"given":"Chisato","family":"Hamashima","sequence":"first","affiliation":[{"name":"Health Policy Section, Department of Nursing, Faculty of Medical Technology, Teikyo University, Itabashi City, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"2021083104305882200_ref1","volume-title":"Cancer Today","author":"International Agency for Research on Cancer (IARC) [Internet]","year":"2020"},{"key":"2021083104305882200_ref2","first-page":"45","volume-title":"IARC Handbooks of Cancer Prevention","author":"International Agency for Research on Cancer (IARC)","year":"2005"},{"key":"2021083104305882200_ref3","volume-title":"The Japanese guidelines for cervical cancer screening","author":"Nakayama T, ed. Research Center on Public Health Science National Cancer Center [Internet]","year":"2019"},{"key":"2021083104305882200_ref4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ygyno.2006.08.053","article-title":"Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies","volume":"104","author":"Koliopoulos","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cncy.22103","article-title":"Meta-analysis of the accuracy of p16 or p16\/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+\/CIN3+ in triage of women with minor abnormal cytology","volume":"127","author":"Peeters","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref6","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.7150\/jca.32743","article-title":"Application of p16\/Ki-67 dual-staining cytology in cervical cancers","volume":"10","author":"Yu","year":"2019","journal-title":"J Cancer"},{"key":"2021083104305882200_ref7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41416-019-0593-4","article-title":"Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis","volume":"121","author":"Kelly","year":"2019","journal-title":"Br J Cancer"},{"key":"2021083104305882200_ref8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-018-2432-z","article-title":"Dual staining for p16\/Ki67 is a more specific test than cytology for triage of HPV-positive women","volume":"473","author":"Are\u00e1n-Cuns","year":"2018","journal-title":"Virchows Arch"},{"key":"2021083104305882200_ref9","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/S0959-8049(02)00462-8","article-title":"New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections","volume":"38","author":"Knebel Doeberitz","year":"2002","journal-title":"Eur J Cancer"},{"key":"2021083104305882200_ref10","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1158\/1055-9965.EPI-08-0306","article-title":"Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia","volume":"17","author":"Cuschieri","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021083104305882200_ref11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ctrv.2008.10.005","article-title":"p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis","volume":"35","author":"Tsoumpou","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"2021083104305882200_ref12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"2021083104305882200_ref13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/dc.20681","article-title":"Interlaboratory reproducibility of liquid-based equivocal cervical cytology within a randomized controlled trial framework","volume":"35","author":"Confortini","year":"2007","journal-title":"Diagn Cytopathol"},{"key":"2021083104305882200_ref14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cncy.21511","article-title":"Interpretation of p16(INK4a) \/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology","volume":"123","author":"Allia","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/cncy.21800","article-title":"Interobserver reproducibility of cytologic p16INK4a \/Ki-67 dual immunostaining in human papillomavirus-positive women","volume":"125","author":"Benevolo","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref16","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.1002\/cam4.3399","article-title":"Implementation of p16\/Ki67 dual stain cytology in a Danish routine screening laboratory: importance of adequate training and experience","volume":"9","author":"Hammer","year":"2020","journal-title":"Cancer Med"},{"key":"2021083104305882200_ref17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/jnci\/djt235","article-title":"Screening for cervical cancer precursors with p16\/Ki-67 dual-stained cytology: results of the PALMS study","volume":"105","author":"Ikenberg","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.20140","article-title":"European CINtec Cytology Study Group. p16\/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study","volume":"119","author":"Schmidt","year":"2011","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/dc.21757","article-title":"Evaluation of testing as an adjunctive test in ASCUS diagnosed SurePath\u00ae preparations","volume":"41","author":"Edgerton","year":"2011","journal-title":"Diagn Cytopathol"},{"key":"2021083104305882200_ref20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cncy.21205","article-title":"p16INK4a immunocytochemistry versus HPV testing for triage of women with minor cytological abnormalities: a systematic review and meta-analysis","volume":"120","author":"Roelens","year":"2012","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncy.21542","article-title":"Prospective evaluation of p16\/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results","volume":"123","author":"Bergeron","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/cncy.21661","article-title":"Triage of ASC-H: a meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer","volume":"124","author":"Xu","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref23","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-12-0270","article-title":"Performance of p16\/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population","volume":"18","author":"Wentzensen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021083104305882200_ref24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ygyno.2011.02.033","article-title":"Triaging pap cytology negative, HPV positive cervical cancer screening results with p16\/Ki-67 dual-stained cytology","volume":"121","author":"Petry","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref25","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/ijc.29290","article-title":"Triaging HPV-positive women with normal cytology by p16\/Ki-67 dual-stained cytology testing: baseline and longitudinal data","volume":"136","author":"Uijterwaal","year":"2015","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref26","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref27","doi-asserted-by":"crossref","first-page":"21181","DOI":"10.18632\/oncotarget.8307","article-title":"Evaluation of p16\/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"2021083104305882200_ref28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","article-title":"Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial","volume":"144","author":"Wright","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2021083104305882200_ref30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/14737159.2014.897610","article-title":"Cancer diagnostic classifiers based on quantitative DNA methylation","volume":"14","author":"Lorincz","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"2021083104305882200_ref31","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J Clin Virol"},{"key":"2021083104305882200_ref32","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1470-2045(14)70019-1","article-title":"Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial","volume":"15","author":"Verhoef","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021083104305882200_ref33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2016.02.012","article-title":"Validation of the FAM19A4\/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women","volume":"141","author":"De Strooper","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrg2732","article-title":"Principles and challenges of genomewide DNA methylation analysis","volume":"11","author":"Laird","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2021083104305882200_ref35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7314\/APJCP.2014.15.2.891","article-title":"PAX1 methylation analysis by MS-HRM is useful in triage of high-grade squamous intraepithelial lesions","volume":"15","author":"Wang","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"2021083104305882200_ref36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.21037\/atm.2016.09.30","article-title":"PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians","volume":"4","author":"Chen","year":"2016","journal-title":"Ann Transl Med"},{"key":"2021083104305882200_ref37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/jnci\/djs135","article-title":"Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population","volume":"104","author":"Mirabello","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref38","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jnci\/djs425","article-title":"Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3","volume":"104","author":"Wentzensen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref39","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/ijc.30008","article-title":"Validation of a DNA methylation HPV triage classifier in a screening sample","volume":"138","author":"Lorincz","year":"2016","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3233\/CBM-150507","article-title":"HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and EPB41L3 methylation classifier","volume":"15","author":"Brentnall","year":"2015","journal-title":"Cancer Biomark"},{"key":"2021083104305882200_ref41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ijc.33314","article-title":"Effective methylation triage of HPV positive women with abnormal cytology in a middle-income country","volume":"148","author":"Ram\u00edrez","year":"2020","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref42","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women","volume":"24","author":"Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021083104305882200_ref43","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2008.10.012","article-title":"Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science","volume":"112","author":"Wentzensen","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref44","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/ijc.27750","article-title":"Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia","volume":"132","author":"Mirabello","year":"2013","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref45","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1002\/ijc.31976","article-title":"Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial","volume":"144","author":"Cook","year":"2019","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref46","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/ijc.28138","article-title":"CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease","volume":"133","author":"Bierkens","year":"2013","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrc3728","article-title":"Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions","volume":"14","author":"Steenbergen","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"2021083104305882200_ref48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/ijc.31539","article-title":"Cervical cancer risk in HPV-positive women after a negative FAM19A4\/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14-year follow-up","volume":"143","author":"De Strooper","year":"2018","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref49","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/cid\/ciz677","article-title":"Methylation in predicting progression of untreated high-grade cervical intraepithelial neoplasia","volume":"70","author":"Louvanto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021083104305882200_ref50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.virol.2013.10.032","article-title":"Methylation of human papillomavirus 16, 18, 31, and 45 L2 and L1 genes and the cellular DAPK gene: considerations for use as biomarkers of the progression of cervical neoplasia","volume":"448","author":"Kalantari","year":"2014","journal-title":"Virology"},{"key":"2021083104305882200_ref51","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/ijc.28790","article-title":"A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes","volume":"135","author":"Brentnall","year":"2014","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref52","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1940-6207.CAPR-13-0091","article-title":"An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China","volume":"6","author":"Zhao","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"2021083104305882200_ref53","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/ijc.28616","article-title":"Lower cost strategies for triage of human papillomavirus DNA-positive women","volume":"134","author":"Qiao","year":"2014","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13148-020-00853-1","article-title":"Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study","volume":"12","author":"Dong","year":"2020","journal-title":"Clin Epigenetics"},{"key":"2021083104305882200_ref55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cjca.2017.01.001","article-title":"MicroRNAs in the pathobiology and therapy of atherosclerosis","volume":"33","author":"Laffont","year":"2017","journal-title":"Can J Cardiol"},{"key":"2021083104305882200_ref56","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/ijc.29618","article-title":"A systematic study on dysregulated microRNAs in cervical cancer development","volume":"138","author":"He","year":"2016","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref57","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/s12885-018-4590-4","article-title":"MicroRNAs as markers of progression in cervical cancer: a systematic review","volume":"18","author":"Pardini","year":"2018","journal-title":"BMC Cancer"},{"key":"2021083104305882200_ref58","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju241","article-title":"MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women","volume":"106","author":"Tian","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-019-0999-x","article-title":"Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors","volume":"18","author":"Zheng","year":"2019","journal-title":"Mol Cancer"},{"key":"2021083104305882200_ref60","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ygyno.2013.06.005","article-title":"Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results","volume":"130","author":"Luhn","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref61","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/path.2070","article-title":"Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer","volume":"210","author":"Hopman","year":"2006","journal-title":"J Pathol"},{"key":"2021083104305882200_ref62","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2353\/ajpath.2009.090122","article-title":"Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears","volume":"175","author":"Andersson","year":"2009","journal-title":"Am J Pathol"},{"key":"2021083104305882200_ref63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergencyto.2009.01.004","article-title":"Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders","volume":"191","author":"Tu","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"key":"2021083104305882200_ref64","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0002-9440(10)62341-3","article-title":"Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer","volume":"166","author":"Heselmeyer-Haddad","year":"2005","journal-title":"Am J Pathol"},{"key":"2021083104305882200_ref65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000371760","article-title":"Can genomic amplification of human telomerase gene and C-MYC in liquid-based cytological specimens be used as a method for opportunistic cervical cancer screening?","volume":"80","author":"Gao","year":"2015","journal-title":"Gynecol Obstet Invest"},{"key":"2021083104305882200_ref66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1746-1596-7-40","article-title":"Genomic amplification patterns of human telomerase RNA gene and C-MYC in liquid-based cytological specimens used for the detection of high-grade cervical intraepithelial neoplasia","volume":"7","author":"Chen","year":"2012","journal-title":"Diagn Pathol"},{"key":"2021083104305882200_ref67","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.7314\/APJCP.2012.13.5.2063","article-title":"Significance of human telomerase RNA gene amplification detection for cervical cancer screening","volume":"13","author":"Chen","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"2021083104305882200_ref68","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/PGP.0b013e318237d50a","article-title":"Genomic amplification of hTERC in paraffin-embedded tissues of cervical intraepithelial neoplasia and invasive cancer","volume":"31","author":"He","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"2021083104305882200_ref69","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3892\/ijmm.2014.1699","article-title":"Detection of hTERC and c-MYC genes in cervical epithelial exfoliated cells for cervical cancer screening","volume":"33","author":"Li","year":"2014","journal-title":"Int J Mol Med"},{"key":"2021083104305882200_ref70","first-page":"518","article-title":"Amplification of TERT and TERC genes in cervical intraepithelial neoplasia and cervical cancer","volume":"35","author":"Visnovsky","year":"2014","journal-title":"Neuro Endocrinol Lett"},{"key":"2021083104305882200_ref71","doi-asserted-by":"crossref","first-page":"51.e1","DOI":"10.1016\/j.ajog.2015.02.001","article-title":"Amplification of the 3q chromosomal region as a specific marker in cervical cancer","volume":"213","author":"Wright","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"2021083104305882200_ref72","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000438719","article-title":"Clinical role of the detection of human telomerase RNA component gene amplification by fluorescence in situ hybridization on liquid-based cervical samples: comparison with human papillomavirus-DNA testing and histopathology","volume":"59","author":"Zappacosta","year":"2015","journal-title":"Acta Cytol"},{"key":"2021083104305882200_ref73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.anndiagpath.2018.02.003","article-title":"Different amplification patterns of 3q26 and 5p15 regions in cervical intraepithelial neoplasia and cervical cancer","volume":"35","author":"Kudela","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"2021083104305882200_ref74","first-page":"2099","article-title":"Genomic amplification of HPV, h-TERC and c-MYC in liquid-based cytological specimens for screening of cervical intraepithelial neoplasia and cancer","volume":"17","author":"Ji","year":"2019","journal-title":"Oncol Lett"},{"key":"2021083104305882200_ref75","volume-title":"Fluorescence In Situ Hybridization (FISH) or Other In Situ Hybridization (ISH) Testing of Uterine Cervical Cells to Predict Precancer and Cancer: Technology Assessment Report","author":"Uhlig","year":"2013"},{"key":"2021083104305882200_ref76","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1007\/s13277-014-1915-z","article-title":"The significant diagnostic value of human telomerase RNA component (hTERC) gene detection in high-grade cervical lesions and invasive cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"key":"2021083104305882200_ref77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.humpath.2004.12.001","article-title":"Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma","volume":"36","author":"Sobel","year":"2005","journal-title":"Hum Pathol"},{"key":"2021083104305882200_ref78","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12253-018-0384-x","article-title":"Dual-stained cervical cytology and histology with claudin-1 and Ki67","volume":"25","author":"Szekercz\u00e9s","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"2021083104305882200_ref79","doi-asserted-by":"crossref","first-page":"298495","DOI":"10.1155\/2008\/298495","article-title":"Correlation of DNA ploidy with progression of cervical cancer","volume":"2008","author":"Singh","year":"2008","journal-title":"J Cancer Epidemiol"},{"key":"2021083104305882200_ref80","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5306\/wjco.v5.i5.931","article-title":"Clinical application of DNA ploidy to cervical cancer screening: a review","volume":"5","author":"Garner","year":"2014","journal-title":"World J Clin Oncol"},{"key":"2021083104305882200_ref81","first-page":"33","article-title":"Detection of cervical cancer and high grade neoplastic lesions by a combination of liquid-based sampling preparation and DNA measurements using automated image cytometry","volume":"27","author":"Sun","year":"2005","journal-title":"Cell Oncol"},{"key":"2021083104305882200_ref82","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ijc.31261","article-title":"Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs","volume":"143","author":"Cuschieri","year":"2018","journal-title":"Int J Cancer"},{"key":"2021083104305882200_ref83","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement","volume":"320","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"key":"2021083104305882200_ref84","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"125","author":"Huh","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2021083104305882200_ref85","author":"Cancer Council Australia, Sydney [Internet]"},{"key":"2021083104305882200_ref86","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021083104305882200_ref87","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5858\/arpa.2012-0493-RA","article-title":"The spectrum of cervical glandular neoplasia and issues in differential diagnosis","volume":"138","author":"Loureiro","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2021083104305882200_ref88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/gyno.2000.5826","article-title":"The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study","volume":"78","author":"Smith","year":"2000","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0090-8258(89)90602-1","article-title":"Increase of cervical adenocarcinoma: a report of 520 cases of cervical carcinoma including 112 tumors with glandular elements","volume":"33","author":"Vesterinen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"2021083104305882200_ref90","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00428-019-02601-0","article-title":"Recent advances in invasive adenocarcinoma of the cervix","volume":"475","author":"Stolnicu","year":"2019","journal-title":"Virchows Arch"},{"key":"2021083104305882200_ref91","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021083104305882200_ref92","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021083104305882200_ref93","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/modpathol.2014.55","article-title":"HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases","volume":"27","author":"Pirog","year":"2014","journal-title":"Mod Pathol"},{"key":"2021083104305882200_ref94","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncy.21557","article-title":"Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China\u2019s largest CAP-certified laboratory","volume":"123","author":"Zheng","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref95","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/cncy.21545","article-title":"History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China","volume":"123","author":"Tao","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref96","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncy.21544","article-title":"Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices","volume":"123","author":"Blatt","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"2021083104305882200_ref97","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2021083104305882200_ref98","volume-title":"WHO Classification of Tumours of the Female Reproductive Organs","author":"Kurman","year":"2014","edition":"4th"},{"key":"2021083104305882200_ref99","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/PAS.0000000000001090","article-title":"Diagnostic algorithmic proposal based on comprehensive immunohistochemical evaluation of 297 invasive endocervical adenocarcinomas","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2021083104305882200_ref100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017225","article-title":"Tumor-suppressor gene SOX1 is a methylation-specific expression gene in cervical adenocarcinoma","volume":"98","author":"Yuan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2021083104305882200_ref101","first-page":"3981529","article-title":"SOX1 and PAX1 are hypermethylated in cervical adenocarcinoma and associated with better prognosis","volume":"2020","author":"Zhao","year":"2020","journal-title":"Biomed Res Int [Internet]"},{"key":"2021083104305882200_ref102","doi-asserted-by":"crossref","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self-samples: updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ [Internet]"},{"key":"2021083104305882200_ref103","doi-asserted-by":"crossref","DOI":"10.31557\/APJCP.2021.22.6.1695","article-title":"National data analysis and systematic review for human resources for cervical cancer screening in Japan","author":"Hamashima","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"2021083104305882200_ref104","volume-title":"Report on Regional Public Health Services and Health Promotion Services","author":"Ministry of Health, Labour and Welfare, Tokyo [Internet]","year":"2017"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1462\/40082883\/hyab109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/9\/1462\/40082883\/hyab109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T04:32:19Z","timestamp":1630384339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/9\/1462\/6318553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":104,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,7,9]]},"published-print":{"date-parts":[[2021,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab109","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,7,9]]}}}